Tvardi Therapeutics (TVRD) Net Margin (2013 - 2025)
Tvardi Therapeutics (TVRD) posted Net Margin of 372.87% for Q1 2025, up 49.39% sequentially from 736.7% in Q4 2024, and up 108048.0% YoY from N/an in Q1 2024.
Tvardi Therapeutics (TVRD) Net Margin (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Net Margin for 13 years, with the latest figure at 372.87% in Q1 2025.
- Quarterly Net Margin rose 108048.0% year-over-year to 372.87% in Q1 2025, while the trailing twelve-month figure through Mar 2025 was 492.27% (up 25912.0% YoY) and the FY2024 annual result came in at 992.95%, down 42774.0% from the prior year.
- Net Margin improved to 372.87% in Q1 2025 per TVRD's latest filing, from 736.7% in the prior quarter.
- Over five years, Net Margin peaked at 5.0% in Q3 2021 and troughed at 4066.02% in Q4 2021.
- A 5-year average of 844.87% and a median of 638.81% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2021 and 2022: Net Margin slumped 413676 bps in 2021, then surged 309083 bps in 2022.
- Over 5 years, Net Margin stood at 4066.02% in 2021, then soared by 76 bps to 975.19% in 2022, then decreased by 13 bps to 1102.2% in 2023, then surged by 33 bps to 736.7% in 2024, then surged by 49 bps to 372.87% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 372.87%, 736.7%, and 386.38% for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -372.87% |
| Dec 31, 2024 | -736.70% |
| Sep 30, 2024 | -386.38% |
| Jun 30, 2024 | -716.04% |
| Mar 31, 2024 | -1,453.35% |
| Dec 31, 2023 | -1,102.20% |
| Sep 30, 2023 | -622.61% |
| Jun 30, 2023 | -473.62% |
| Mar 31, 2023 | -472.80% |
| Dec 31, 2022 | -975.19% |
| Sep 30, 2022 | -243.51% |
| Jun 30, 2022 | -32.38% |
| Mar 31, 2022 | -655.01% |
| Dec 31, 2021 | -4,066.02% |
| Sep 30, 2021 | -5.00% |
| Mar 31, 2021 | -1,204.19% |
| Dec 31, 2020 | 70.74% |
| Sep 30, 2020 | -178.17% |
| Jun 30, 2020 | -444.94% |
| Mar 31, 2020 | -357.37% |